An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amgen Announces Positive Top-Line Phase 3 Results for TED Treatment On April 6, Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active thyroid...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Foundayo™ Weight Loss GLP-1 Pill On April 1, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Novo Nordisk’s Awiqli® On March 26, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism On January 7, Rezolute, Inc., a late-stage rare disease company focused on treating hypoglycemia caused by all forms...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience On December 4, Insulet Corporation, announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease On Nov. 6, Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA® (finerenone) significantly reduced urine albumin-to-creatinine...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Study Shows BDI Screening of Existing Patient CT Scans for Undetected Osteoporosis Also Finds Undetected Cardiovascular Disease Risk Many studies have shown the inverse relationship between bone mineral density (BMD) – the gold standard measure for osteopenia/osteoporosis – and coronary calcium...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * New Study Shows that Ozempic® Reduces the Risk of Heart Attack, Stroke, and Death by 23% Compared to Dulaglutide On September 18, Novo Nordisk announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was...
